Oppenheimer initiates Passage Bio stock with outperform rating

Oppenheimer has initiated coverage of Passage Bio Inc. (NASDAQ:PASG) with an outperform rating and a price target of $30.00, suggesting a significant upside of 385% from its current price. The firm believes the stock's 46% year-to-date decline is an overreaction to competitor program failures and regulatory concerns, presenting a buying opportunity. Oppenheimer highlighted key differentiators for Passage Bio's lead asset PBFT02 in frontotemporal dementia, projecting $1 billion in peak risk-adjusted sales by 2040.

Original reporting
Investing.com · Investing.com
Published Mar 31, 2026, 1:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 31, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer initiates Passage Bio stock with outperform rating — source image
Decision brief

The 30-second read

$PASGBullishHigh
01

Why it matters

The analyst's positive outlook may catalyze a short-term rally, but underlying risks remain.

02

Market read

The coverage and target price could influence investor sentiment and trading volume in PASG.

03

What to watch

Potential delays in PBFT02 development or unforeseen regulatory challenges could limit upside.

Relevance 6/10Timing: Immediate, as the news is recent and impacts short-term sentiment.

Background

Passage Bio experienced a 46% decline year-to-date, attributed to sector-wide concerns and specific program setbacks.

Company-level read

Ticker impact

$PASGBullishHigh confidence
Context

High relevance due to recent analyst upgrade and significant upside potential.

Expected impact

Potential upward movement toward the $30 target, representing approximately 385% upside from current levels.

Evidence & confidence

The analyst's strong buy rating, high price target, and belief that recent declines are overreactions support a bullish outlook.

Market effects

Positive impact on the life sciences sector, especially biotech stocks with similar profiles.

Potential uplift in US biotech indices.

Limited, as Passage Bio is a US-based company with specific focus.

Counterpoint

The recent decline may reflect underlying issues not fully addressed by the analyst, such as regulatory hurdles or clinical trial setbacks.

Key entities

  • Passage Bio Inc.

    Biotech firm focusing on gene therapies for neurodegenerative diseases.

  • Oppenheimer

    Investment bank initiating coverage with a bullish rating.

Related articles

$PASGMed

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.